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Transforming growth factor-b (TGF-b)-mediated signals play complicated roles in the development and progression of breast
tumour. The purposes of this study were to analyse the genotype of TGF-b1 at T29C and TGF-b1 phenotype in breast tumours, and
to evaluate their associations with IGFs and clinical characteristics of breast cancer. Fresh tumour samples were collected from 348
breast cancer patients. TGF-b1 genotype and phenotype were analysed with TaqMan
s and ELISA, respectively. Members of the IGF
family in tumour tissue were measured with ELISA. Cox proportional hazards regression analysis was performed to assess the
association of TGF-b1 and disease outcomes. Patients with the T/T (29%) genotype at T29C had the highest TGF-b1, 707.9 pgmg
 1,
followed by the T/C (49%), 657.8 pgmg
 1, and C/C (22%) genotypes, 640.8 pgmg
 1,( P¼0.210, T/T vs C/C and C/T). TGF-b1
concentrations were positively correlated with levels of oestrogen receptor, IGF-I, IGF-II and IGFBP-3. Survival analysis showed
TGF-b1 associated with disease progression, but the association differed by disease stage. For early-stage disease, patients with the
T/T genotype or high TGF-b1 had shorter overall survival compared to those without T/T or with low TGF-b1; the hazard ratios
(HR) were 3.54 (95% CI: 1.21–10.40) for genotype and 2.54 (95% CI: 1.10–5.89) for phenotype after adjusting for age, grade,
histotype and receptor status. For late-stage disease, however, the association was different. The T/T genotype was associated with
lower risk of disease recurrence (HR¼0.13, 95% CI: 0.02–1.00), whereas no association was found between TGF-b1 phenotype
and survival outcomes. The study suggests a complex role of TGF-b1 in breast cancer progression, which supports the finding of
in vitro studies that TGF-b1 has conflicting effects on tumour growth and metastasis.
British Journal of Cancer (2008) 99, 1357–1363. doi:10.1038/sj.bjc.6604689 www.bjcancer.com
Published online 30 September 2008
& 2008 Cancer Research UK
Keywords: TGF-b1; polymorphism; IGFs; breast cancer; survival
                                                       
Transforming growth factor-b (TGF-b) is a group of multi-
functional proteins, which include three TGF-b isoforms (TGF-b1,
-b2, -b3) and several other polypeptides. These growth factors
regulate important cellular activities, including cell proliferation,
differentiation, apoptosis and motility, and the formation of
extracellular matrix. The actions of TGF-b are mediated through a
cell membrane receptor TGF-b receptor II (TbRII), which, upon
binding to its ligand, recruits another TGF-b receptor (TbRI)
forming a receptor heterodimer. The formation activates the
receptor’s serine/threonine kinase, which phosphorylates Smad2
or Smad3. The phosphorylated Smad2/3 forms a complex with
Smad4 which moves to the nucleus and binds to DNA targets
initiating complicated TGF-b effects (Dumont and Arteaga, 2000;
Wakefield et al, 2001; Buck and Knabbe, 2006; Chang et al, 2007;
Cox et al, 2007).
Evidence suggests that TGF-b-mediated signals are important in
the development and growth of breast tissues (Wakefield et al,
2001). TGF-b is involved in the formation of mammary gland
architecture, regulation of stem cell kinetics, maintenance of
mammary epithelium in a functionally undifferentiated state, and
initiation of apoptosis in gland involution. Both in vitro and
in vivo experiments have shown that TGF-b inhibits the
proliferation of mammary epithelial cells. In TGF-b1 and TGF-a
double-transgenic mice, tumour occurrence was significantly
reduced compared to the animals with TGF-a transgene alone.
In addition, mammary gland tumorigenesis induced by 7, 12-
dimethybenz[a] anthracene was prevented by TGF-b expression.
TGF-b induces premature senescence of mammary stem cells and
thus may suppress tumour development (Pierce et al, 1995; Siegel
and Massague, 2003). Evidence, however, also suggests that TGF-b
may stimulate tumorigenesis in epithelial cells through inducing
epithelial-to-mesenchymal transition, disrupting cell adhesion,
and enhancing cell invasiveness (Miettinen et al, 1994; Oft et al,
1996; Knudsen et al, 1998; Blobe et al, 2000). TGF-b1 upregulates
integrin-linked kinase, and increases cell motility. Recent studies
have shown that alterations in TGF-b signalling have biphasic
effects on tumour progression and metastasis (Tang et al, 2003;
Serra and Crowley, 2005; Chang et al, 2007).
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sTGF-b1 is the most abundant TGF-b in many tissues. The
TGF-b1 gene is located on chromosome 19q13, and is expressed
as a 25-kDa protein in endothelial and haematopoietic cells, as well
as in connective tissues (Chang et al, 2007). Several genetic
polymorphisms exist in the TGF-b1 gene, one of which is a
T-C transition at nucleotide 29 of the coding region, resulting in
a leucine to proline substitution at codon 10 (Blobe et al, 2000;
Breast Cancer Association Consortium, 2006; Cox et al, 2007). This
single nucleotide polymorphism (SNP) T29C, which is in strong
linkage disequilibrium with another common SNP C-509T, has
been studied extensively for its association with breast cancer risk
and survival (Yokota et al, 2000; Goode et al, 2002; Hishida et al,
2003; Krippl et al, 2003; Ziv et al, 2003; Jin et al, 2004; Le Marchand
et al, 2004; Shu et al, 2004; Kaklamani et al, 2005; Lee et al, 2005;
Shin et al, 2005; Skerrett et al, 2005; Breast Cancer Association
Consortium, 2006; Feigelson et al, 2006; Gonzalez-Zuloeta Ladd
et al, 2007). Two studies found increased risk of breast cancer
among Koreans and Dutch who carry the C allele (Lee et al, 2005;
Gonzalez-Zuloeta Ladd et al, 2007), whereas two other studies
showed decreased risk in relation to C genotype among Americans
who were older than 65 years or Japanese who were premeno-
pausal (Hishida et al, 2003; Ziv et al, 2003). Another study
conducted in China observed the association varied by disease
stage (Shin et al, 2005). Reduced disease-free survival in patients
who carried the C allele was observed in some (Shu et al, 2004;
Skerrett et al, 2005), but not other studies (Goode et al, 2002;
Gonzalez-Zuloeta Ladd et al, 2007). The C allele at T29C has been
associated with high levels of circulating TGF-b1 in a Japanese
study (Yokota et al, 2000), but no studies have evaluated this
relationship in breast tissue.
Associations of TGF-b1 concentrations in tumour tissue and
breast cancer survival have been examined in a number of studies,
and the results were inconsistent. Several studies found high
TGF-b1 being associated with poor survival (Gorsch et al, 1992;
Walker and Dearing, 1992; Dalal et al, 1993; Walker et al, 1994;
Desruisseau et al, 2006), whereas others showed an opposite
association (Murray et al, 1993; Kesari et al, 1999). Most of the
studies used semi-quantitative immunohistochemical staining to
assess TGF-b1 levels in breast tumours. There was only one study
using ELISA to measure TGF-b1 in tissue samples, and the study
found high TGF-b1 in association with poor survival in node-
negative, but not in node-positive patients (Desruisseau et al,
2006). Studies also suggest possible synergies between TGF-b and
insulin-like growth factors (IGFs) (Tsukazaki et al, 1994; Wong
et al, 2001). To further elucidate the role of TGF-b1 in breast
cancer, we analysed TGF-b1 genotype at T29C and protein levels in
tumour samples, and examined the associations of these markers




Patients who underwent surgery for beast cancer in the
Gynecologic Oncology Unit at University of Turin in Italy between
January 1998 and July 1999 were recruited for the study, which was
approved by the university’s ethical review committee. During the
study, fresh tumour samples were collected from 348 patients; the
specimens were snap-frozen in liquid nitrogen immediately after
resection and then stored at  801C until analysis. Clinical
information collected for the study includes age at surgery, disease
stage, tumour grade, tumour size, number of lymph nodes tested
positive for cancer, histological type and hormone receptor status.
Of the 348 patients, 302 were followed from surgery through
February 2007; during the follow-up, information on relapse and
death was collected.
Tumour tissue analysis
Frozen tumour samples were pulverised manually in liquid
nitrogen. Genomic DNA was extracted from approximately
100mg of tissue powder following a standard phenol–chloroform
protocol. SNP genotype at T29C of TGF-b1 was analysed with a
TaqMan assay (PN: C_22272997, Applied Biosystems, Foster City,
CA, USA). The PCR procedure consisted of initial denaturing at
951C for 10min, and 50 cycles of denaturing at 921C for 15s and
annealing/extension at 681C for 1min. The PCR was carried out in
the ABI 7500 system with about 10ng of genomic DNA.
Tissue proteins were extracted from approximately 100mg of
tissue powder using a commercial kit (Clonetech, Palo Alto, CA,
USA). The extraction was done through mixing the tissue power
with 1ml BD TALON Tractor buffer, and collecting supernatant
after centrifuging the mixture at 14000r.p.m. for 30min at 41C.
Concentrations of total protein in tissue extracts were measured
using the bicinchoninic acid method (Pierce Inc., Rockford, IL,
USA). A commercial ELISA kit for human TGF-b1 (R&D Systems
Inc., Minneapolis, MN, USA) was used to determine TGF-b1
concentration in tumour samples (DB100B). The assay was
performed following the manufacturer’s instruction. The amount
of TGF-b1 in tumour samples was measured after the latent
TGF-b1 was activated by acid-treatment (activation by 1N HCI and
neutralisation by 1.2N NaOH). All the specimens were tested in
duplicate after the 2-fold dilution. If the concentration of TGF-b1
exceeded the highest standard after dilution, the sample was
further diluted and re-measured. The measurement was repeated if
the CV (coefficient of variation) on the duplicate was greater than
10%. The final concentration of TGF-b1 in each sample was
adjusted for total protein. Tissue levels of IGF-I, IGF-II and IGFBP-
3 were analysed in the same samples for a previous study of IGFs
(Mu et al, 2008). Four commercial ELISA kits (Diagnostic Systems
Laboratories, Webster, TX, USA) were used to measure the
concentrations of IGF-I, free-IGF-I, IGF-II and IGFBP-3 in tumour
samples, and the measurement was carried out in the same manner
as that for TGF-b1 described above. Tumour hormone receptor
status, including oestrogen receptor (ER) and progesterone
receptor (PR), was measured routinely in the clinic to assist
post-operative treatment.
Statistic analysis
TGF-b1 genotype and phenotype were compared among patients
with different clinical and pathological features using the Wilcoxon
rank sum test or w
2 test where appropriate. Correlations of TGF-b1
protein with numerical or ordinal variables were analysed using
the Spearman correlation coefficient. Cox proportional hazard
regression models were employed for survival analysis. In the
analysis, tissue levels of TGF-b1 were grouped into low, medium
and high categories based on their tertile distribution. Low
category was used as reference in data analysis. Disease-free
survival was the time interval from the date of surgery to date of
recurrence or last follow-up. Overall survival was the time between
the date of surgery and date of breast cancer death or last follow-
up. Hazard ratios and their 95% confidence intervals were
calculated at both univariate and multivariate levels. Age at
surgery, TNM stage, tumour grade, histological type, oestrogen
receptor and progesterone receptor were included in the multi-
variate analysis.
RESULTS
TGF-b1 genotype and phenotype in breast cancer
For the TGF-b1 genotype at T29C, 101 patients (29%) carried the
T/T genotype, 78 (22%) had the C/C genotype, and 169 (49%) were
heterozygous T/C. TGF-b1 protein was detectable in all the tumour
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ssamples, and the median concentration was 662.2pgmg
 1, ranging
from 56.6 to 3640.4pgmg
 1. Figure 1 shows the level of TGF-b1i n
tumour tissue by different genotypes of TGF-b1 at T29C. The
highest level of TGF-b1 was seen in the T/T genotype (median:
707.9pgmg
 1). The average TGF-b1 levels were 657.8 and
640.8pgmg
 1 in the T/C and C/C carriers, respectively. The
differences in tissue levels of TGF-b1 by the genotype, however,
were not statistically significant (P¼0.210).
Associations of TGF-b1 with disease characteristics and
IGF expression
Comparisons of TGF-b1 genotype and phenotype over different
disease characteristics are shown in Table 1. No significant
association was observed between TGF-b1 genotype and clinical
characteristics of breast cancer. However, TGF-b1 protein levels
were significantly different by TNM stage and ER status. Higher
TGF-b1 was found in early-stage disease (Stage I/II) or ER-positive
tumours. Levels of TGF-b1 were significantly correlated with
disease stage (r¼ 0.14) and ER status (r¼0.18) (Table 2).
Peptide levels of IGF markers measured in our previous study (Mu
et al, 2008) were also evaluated for their relationship with TGF-b1.
The analysis showed that the protein was positively correlated with
IGF-I (r¼0.13), IGF-II (r¼0.33) and IGFBP-3 (r¼0.23) (Table 2).
TGF-b1 genotype and phenotype in relation to patient
survival
Table 3 shows the associations of TGF-b1 genotype and phenotype
with disease-free and overall survival (DFS and OS). When
analysing all patients together, we found no significant associa-
tions between DFS and TGF-b1, either genotype or phenotype.
However, OS was associated with TGF-b1 genotype, but not
phenotype. Patients with the T/T genotype had more than 2-fold
increases in risk of breast cancer death (P¼0.013). This
association was more evident among patients with early-stage
disease. Both TGF-b1 genotype and phenotype were associated
with OS. Patients with stage I or II breast cancer had 4-fold
increases in risk of death if they had the T/T genotype compared
with C/C (P¼0.002) or 2-fold increases in risk of death if they had
high compared with low TGF-b1( P¼0.030). The trends for
increasing risk of death from the C/C to C/T to T/T genotype or
from low to median to high TGF-b1 were also significant, and









































Figure 1 TGF-b1 genotype and phenotype in breast tumour tissue.
Table 1 Associations of TGF-b1 genotype and phenotype with
clinicopathological characteristics of breast cancer
TGF-b1 genotype TGF-b1
phenotype












o50 111 21 58 32 653.9
50B65 139 30 69 40 640.8
65B 98 27 42 29 669.3
P-value 0.589 0.562
Histological type
Ductal 230 46 113 71 712.8
Lobular 75 17 39 19 574.7
Others 42 15 17 10 649.8
P-value 0.224 0.135
Tumour size (cm)
p2 206 41 111 54 667.6
42 140 37 57 46 640.1
P-value 0.054 0.798
Lymph node
Negative 183 42 87 54 659.5
Positive 159 35 78 46 673.3
P-value 0.959 0.468
Tumour grade
G1/2 199 48 98 53 680.3
G3 144 30 67 47 611.4
P-value 0.459 0.153
TNM stage
Stage I-II 310 67 154 89 674.5
Stage III-IV 31 10 10 11 497.1
P-value 0.163 0.010
Oestrogen receptor (%)
o10 126 20 62 44 558.2
X10 222 58 107 57 717.6
P-value 0.046 0.001
Progesterone receptor (%)
o10 169 41 72 56 658.8
X10 179 37 97 45 665.7
P-value 0.090 0.574
aRange: 25–75%.

















TGF-b1 Protein 0.04  0.03 0.01  0.06  0.14* 0.18** 0.05 0.13*  0.04 0.33*** 0.23***
*Po0.05, **Po0.01, ***Po0.001.
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sER/PR status (Table 3). Similar associations, however, were not
observed for patients with late-stage disease. Among patients with
stage III or IV disease, the risk for relapse or death was lower in the
T/T genotype compared with C/C genotype or lower in high
compared with low TGF-b1, although most of the associations
were not statistically significant except for one.
DISCUSSION
The distribution of the T29C genotype in our study population was
quite similar to those reported in Polish (Jin et al, 2004), African
American and Latino (Le Marchand et al, 2004), but the C/C
genotype in our study was slightly higher than that in Finnish,
German and Dutch (Jin et al, 2004), and relatively lower than that
in Japanese, Hawaii and Chinese (Le Marchand et al, 2004). We
found no significant association of this polymorphism with breast
cancer progression when analysing all the patients together.
However, the results were different when the analysis was stratified
by disease stage. The T/T genotype was associated with increased
risk of relapse in patients with early-stage disease, but not in
patients with late-stage disease. Consistent with the finding of
disease-free survival, overall survival was also associated with the
TGF-b1 genotype. Patients with the T/T genotype had significantly
higher risk of death than those without the genotype. The elevated
risk was more evident in patients with early-stage disease, and
remained significant after adjusting for clinical and pathological
factors. More importantly, similar associations were also observed
for the TGF-b1 phenotype. High levels of TGF-b1 protein, which
were in the same direction as the T/T genotype, were associated
with increased risk of disease progression and death, and the
association was especially substantial for overall survival and was
independent of other factors.
These associations, however, were not observed in patients with
late-stage disease. In fact, the associations of TGF-b1 with disease
progression and death in late-stage patients were in an opposite
direction; patients with the genotype and phenotype of high TGF-
b1 seemed to have reduced risk of disease progression or death,
although most of the associations were not statistically significant.
The apparently opposite relationship between TGF-b1 and disease
progression suggests that TGF-b1 may have different effects on
breast cancer progression depending on the stage of the disease.
The effect of TGF-b1 on breast cancer survival has been evaluated
by several previous studies, and the findings are quite inconsistent.
Two studies observed shorter survival among the C allele carriers
(Shu et al, 2004; Skerrett et al, 2005), whereas one showed longer
survival (Gonzalez-Zuloeta Ladd et al, 2007). Another study found
no association (Goode et al, 2002). Of these studies, none has
analysed the association by disease stage. Interestingly, our results
seem to be in agreement with those of the studies, which evaluated
Table 3 TGF-b1 genotype, phenotype and breast cancer survival
Disease-free survival Overall survival
TGF-b1 HR (95%CI) AHR (95%CI)




C/C 1 1 1 1
T/C 0.75 (0.41–1.36) 0.78 (0.43–1.43) 1.01 (0.46–2.21) 1.20 (0.54–2.67)
T/T 1.54 (0.86–2.76) 1.14 (0.62–2.09) 2.21 (1.04–4.72) 1.87 (0.86–4.08)
Ptrend 0.063 0.511 0.013 0.079
Stage I/II
C/C 1 1 1 1
T/C 1.05 (0.50–2.18) 1.03 (0.49–2.16) 1.79 (0.60–5.32) 1.87 (0.62–5.63)
T/T 2.20 (1.06–4.47) 1.79 (0.86–3.73) 4.03 (1.39–11.69) 3.54 (1.21–10.40)
Ptrend 0.010 0.059 0.002 0.007
Stage III/IV
C/C 1 1 1 1
T/C 0.53 (0.15–1.83) 0.38 (0.08–1.74) 0.70 (0.17–2.94) 1.42 (0.26–7.71)
T/T 0.53 (0.17–1.68) 0.13 (0.02–1.00) 0.77 (0.20–2.88) 0.82 (0.17–3.97)
Ptrend 0.278 0.043 0.686 0.837
TGF-b1 phenotype
Total
Low 1 1 1 1
Medium 0.87 (0.50–1.50) 0.96 (0.54–1.68) 0.99 (0.51–1.94) 1.06 (0.54–2.10)
High 1.14 (0.68–1.93) 1.23 (0.72–2.12) 1.34 (0.70–2.53) 1.41 (0.73–2.72)
Ptrend 0.624 0.449 0.370 0.303
Stage I/II
Low 1 1 1 1
Medium 1.06 (0.56–2.02) 1.24 (0.64–2.42) 1.69 (0.72–3.98) 1.80 (0.76–4.29)
High 1.55 (0.85–2.85) 1.78 (0.94–3.37) 2.43 (1.07–5.51) 2.54 (1.10–5.89)
Ptrend 0.140 0.069 0.030 0.027
Stage III/IV
Low 1 1 1 1
Medium 0.53 (0.17–1.70) 0.29 (0.06–1.45) 0.34 (0.07–1.59) 0.66 (0.09–4.72)
High 0.32 (0.07–1.49) 0.24 (0.04–1.25) 0.21 (0.03–1.67) 0.19 (0.02–1.68)
Ptrend 0.106 0.076 0.071 0.120
aAdjusted Hazard Ratio, adjusting for age, grade, TNM stage (only adjusted when all subjects were analysed), histotype, ER, PR.
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sthe effect of TGF-b1 genotype on breast cancer risk. Two studies
found that women with TGF-b1 C allele had lower risk for early-
stage breast cancer, but higher risk for late-stage disease
(Shin et al, 2005; Feigelson et al, 2006).
Both in vitro and in vivo experiments have shown that TGF-b1i s
expressed in breast cancer. Our study also demonstrated that
TGF-b1 was detectable in breast tumours by ELISA, and the median
concentration was 662.2 pgmg
 1. Furthermore, we found that TGF-
b1 levels were slightly different by the TGF-b1g e n o t y p ea tT 2 9 C
with low concentrations in the C allele carriers. This finding was in
agreement with a previous study in which the C/C genotype was
called a low production genotype and the T/T genotype was a high
production one (Skerrett et al, 2005). We also found in the study
that TGF-b1 levels in tumour tissues were positively correlated with
the concentrations of IGF-I, IGF-II, and IGFBP-3. These IGF
markers were analysed in our previous study where we found no
indications of associations between tissue levels of IGF peptides and
disease-free or overall survival among the same patients (Mu et al,
2008). The correlations between TGF-b1 and IGFs may suggest a
potential synergy between these growth factors or a shared or
related mechanism involving the regulation of these molecules.
Synergistic interaction between TGF-b1 and IGFs was suggested by
an in vitro experiment (Tsukazaki et al,1 9 9 4 ) .T G F - b1 and IGF-I
were found to work in concert in regulating the activity of an
oestrogen-metabolising enzyme called estradiol-17-b hydroxy-
steroid dehydrogenase in MCF-7 cells (Wong et al, 2001). Jointly
elevated TGF-b1 and IGF-I were also seen in sera and local tissues
under other pathological conditions (Li et al, 2002; Stracke et al,
2002). Thus, our finding of positive correlations between TGF-b1
and IGFs in breast cancer does not seem to be unexpected, and it
may have some biologic implications in the disease.
Our survival analysis suggests that the effect of TGF-b1o n
breast cancer progression may be quite different depending on the
stage of the disease. High TGF-b1 was associated with increased
risk of disease progression and death among patients with
early-stage disease, but with decreased risk among patients with
late-stage disease. Similar results were also observed in a previous
study, which was the only study that quantitatively measured
TGF-b1 levels in breast tumours using ELISA. That study found
high TGF-b1 associated with poor DFS in node-negative, but not in
node-positive patients. It also observed TGF-b1 levels in asso-
ciation with disease characteristics depending on nodal status.
ER-negative tumours had lower TGF-b1 than ER-positive ones if
patients were node-negative. However, for node-positive patients,
ER-positive tumours had lower TGF-b1 than ER-negative ones
(Desruisseau et al, 2006). These findings seem to support the
possibility that TGF-b1 may have different functions in breast
cancer progression depending on the stage of the disease.
It is known that the actions of TGF-b1 differ substantially by
its location. Although cellular TGF-b1 inhibits tumour growth,
TGF-b1 in extracellular matrix stimulates tumour cell motility and
migration, facilitating cancer invasion and metastasis (Arteaga
et al, 1990; Reiss, 1999; Barcellos-Hoff, 2005). In mammary gland,
TGF-b1 is a potent inhibitor of cell proliferation, and in certain
circumstances it can also induce apoptosis (Silberstein and Daniel,
1987; Nguyen et al, 2000). Studies have shown that when tumour
develops, the expression of TbRII by breast cancer cells is
diminished, which results in reduced response of tumour cells to
TGF-b1 signalling and increased secretion of the ligand (Akhurst
and Balmain, 1999; Reiss, 1999). Under this situation, the
inhibitory effect of TGF-b1 on tumour cells is diminished or
abrogated. Studies of TGF-b1 signal transduction provided further
evidence that low expression of TbRII by breast cancer cells was
correlated with enhanced in vivo malignant behaviours both in
tumour specimens and a cancer cell line (Gobbi et al, 1999). Tobin
et al, (2002) observed a marked enhancement of tumour growth in
vivo by tumour-derived TGF-b when an autocrine loop was left
intact. Studies also found that increased production of TGF-b1b y
tumour cells was associated with potential invasiveness and
metastasis of cancer (Gorsch et al, 1992; Dalal et al, 1993; Ueki
et al, 1993; Tobin et al, 2002).
It was noted that tumour cells with increased production of
TGF-b1, which could inhibit tumour cell growth in vitro,
stimulated vigorous tumour growth in vivo when the cells were
inoculated into an animal model (Steiner and Barrack, 1992; Chang
et al, 1993). The conflicting results suggest the effect of TGF-b1
may be regulated by multiple mechanisms, and the tumour–host
interaction may play an important role in tumour growth. TGF-b
signalling appeared to have a dual role in mammary tumour
progression in transgenic mice. In Neu transgenic mice, constitu-
tively active TbR1 prolonged the latency of mammary tumour
formation, but enhanced the frequency of lung metastasis. In
contrast, dominant-negative TbRII reduced tumour metastasis in
Neu mice, but shortened the median latency of tumours induced
by polyomavirus middle-T. It was also reported that TbRII
inactivation increased the invasiveness of premalignant or low-
grade breast tumours, but reduced the metastasis of high-grade
tumours (Tang et al, 2003).
To conclude, the study results suggest that TGF-b1 may play a
biphasic role in breast cancer progression depending on the stage
of the disease. High TGF-b1 in early-stage disease may indicate the
lack of TGF-b1 inhibition because of loss of receptors, which
results in unfavourable prognosis. High TGF-b1 may also facilitate
tumour metastasis and invasion leading to increased risk of
disease progression and death.
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